🕊️Fran Bermúdez-Jiménez (@franbermudz) 's Twitter Profile
🕊️Fran Bermúdez-Jiménez

@franbermudz

Juan Rodés | MD, PhD | CNIC HU Virgen de las Nieves, Granada, Spain.
HF and Inherited CV diseases
ORCid: orcid.org/0000-0003-0325…

ID: 360551304

calendar_today23-08-2011 11:44:24

5,5K Tweet

1,1K Followers

592 Following

🕊️Fran Bermúdez-Jiménez (@franbermudz) 's Twitter Profile Photo

Disruption of cTnT-Mediated Sarcomere–Mitochondrial Communication Results in Dilated Cardiomyopathy ahajournals.org/doi/10.1161/CI…

🕊️Fran Bermúdez-Jiménez (@franbermudz) 's Twitter Profile Photo

The Diagnostic and Prognostic Value of the 12-Lead ECG in Arrhythmogenic Left Ventricular Cardiomyopathy | JACC: Advances jacc.org/doi/10.1016/j.…

Sara Inglis (@sarainglismbbch) 's Twitter Profile Photo

New JACC Journals #JACCHF   ⭐️Clinical profiles & occurrence of SCD by #HCM phenotype ⭐️Performance validation of current guidelines doi: 10.1016/j.jchf.2024.12.006.

New <a href="/JACCJournals/">JACC Journals</a> #JACCHF
 
⭐️Clinical profiles &amp; occurrence of SCD by #HCM phenotype
⭐️Performance validation of current guidelines

doi: 10.1016/j.jchf.2024.12.006.
Muthu Vaduganathan (@mvaduganathan) 's Twitter Profile Photo

#CONFIDENCE 1⃣ + 1⃣ = 2⃣ Remarkably, kidney protection with combination therapy mathematically identical to what would be expected based on each monotherapy Finerenone (0.68) * Empagliflozin (0.71) Combination (Expected if Fully Additive): 0.48 Combination (Observed): 0.48

#CONFIDENCE  1⃣ + 1⃣ = 2⃣

Remarkably, kidney protection with combination therapy mathematically identical to what would be expected based on each monotherapy

Finerenone (0.68) * Empagliflozin (0.71)

Combination (Expected if Fully Additive): 0.48

Combination (Observed): 0.48
🕊️Fran Bermúdez-Jiménez (@franbermudz) 's Twitter Profile Photo

ALPK3 Heterozygous Truncating Variants Cause Late-Onset Hypertrophic Cardiomyopathy With Frequent Apical Involvement and Apical Aneurysm | Circulation: Genomic and Precision Medicine ahajournals.org/doi/10.1161/CI…

Circulation (@circaha) 's Twitter Profile Photo

#OriginalResearch: DSc-2mRNA treatment exhibits a therapeutic potential in the treatment of ARVC on animal models, establishing a foundation for prospective clinical applications. #AHAJournals Yan Zou Jennifer Wong Yuxiang Dai ahajrnls.org/44bwcYw

#OriginalResearch: DSc-2mRNA treatment exhibits a therapeutic potential in the treatment of ARVC on animal models, establishing a foundation for prospective clinical applications. #AHAJournals <a href="/YanZouMDPhD/">Yan Zou</a> <a href="/JenniferWongMD/">Jennifer Wong</a> <a href="/YuxiangDaiMD/">Yuxiang Dai</a> ahajrnls.org/44bwcYw
Michael Weintraub, MD (@mweintraubmd) 's Twitter Profile Photo

An argument for reduced dosing frequency of GLP-1s 💉 to maintain long-term weight loss ⚖️, based on mathematical modeling 📊: ➡️ Switching semaglutide from 1x/week to 1x/2 weeks = 50% fewer doses but 72% of weight loss retained ✅ ➡️ 1x/month may preserve ~50% of weight loss 🗓️

An argument for reduced dosing frequency of GLP-1s 💉 to maintain long-term weight loss ⚖️, based on mathematical modeling 📊:

➡️ Switching semaglutide from 1x/week to 1x/2 weeks = 50% fewer doses but 72% of weight loss retained ✅
➡️ 1x/month may preserve ~50% of weight loss 🗓️
JACC Journals (@jaccjournals) 's Twitter Profile Photo

🆕 ACC Scientific Statement on managing #obesity in adults w/ #HF reviews Dx, evaluation, & risk assessment; outlines HF-specific Tx strategies including lifestyle changes, medications, & surgery; & highlights 🔑 evidence gaps & future directions jacc.org/doi/10.1016/j.… #JACC

🆕 ACC Scientific Statement on managing #obesity in adults w/ #HF reviews Dx, evaluation, &amp; risk assessment; outlines HF-specific Tx strategies including lifestyle changes, medications, &amp; surgery; &amp; highlights 🔑 evidence gaps &amp; future directions jacc.org/doi/10.1016/j.… #JACC
🕊️Fran Bermúdez-Jiménez (@franbermudz) 's Twitter Profile Photo

Family Screening in Relatives at Risk for Plakophilin-2–Associated Arrhythmogenic Right Ventricular Cardiomyopathy ahajournals.org/doi/10.1161/CI…

JACC Journals (@jaccjournals) 's Twitter Profile Photo

From ignored to essential: #HeartFailure with improved EF isn’t a footnote anymore. This #JACC review charts a path from vague definitions to clinical clarity. jacc.org/doi/10.1016/j.… #HFimpEF #LVEF

From ignored to essential: #HeartFailure with improved EF isn’t a footnote anymore. This #JACC review charts a path from vague definitions to clinical clarity. jacc.org/doi/10.1016/j.…

#HFimpEF #LVEF
Jef Van den Eynde (@jefvandeneynde) 's Twitter Profile Photo

🚨 Heart failure (HF) decongestion ≠ simple fluid removal. Let’s explore the fascinating electrolyte changes happening behind the scenes and how they interact with diuretic therapy. 🫀💧⚡ Here follows a thread.🧵 Full review by Frederik H. Verbrugge and me: onlinelibrary.wiley.com/doi/10.1002/ej…

🕊️Fran Bermúdez-Jiménez (@franbermudz) 's Twitter Profile Photo

The Relevance of the Type of Ventricular Arrhythmia in Titin-Related Dilated Cardiomyopathy: A Multicenter Study | JACC: Clinical Electrophysiology Small cohort of TTNtvs with high arrhythmic burden (PVCs) or SMVT. SMVT origin: septal predominance Complete abolition of PVCs

The Relevance of the Type of Ventricular Arrhythmia in Titin-Related Dilated Cardiomyopathy: A Multicenter Study | JACC: Clinical Electrophysiology 

Small cohort of TTNtvs with high arrhythmic burden (PVCs) or SMVT. 
SMVT origin: septal predominance
Complete abolition of PVCs
🕊️Fran Bermúdez-Jiménez (@franbermudz) 's Twitter Profile Photo

Universal application of CEP devices during TAVI do not appear to lead to measurable clinical benefit in an unselected population Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation | New England Journal of Medicine nejm.org/doi/full/10.10…

Michael "Mike" Albert, MD (@michaelalbertmd) 's Twitter Profile Photo

🧠 Tirzepatide doesn’t just reduce appetite—it rewires the brain. - - - A new Nature Medicine Phase 1 RCT (n=114) explored how tirzepatide changes eating behavior—and the brain’s response to food—in people with overweight or obesity. 📉 Key Findings at 3–6 Weeks 🔹-524 kcal/day

🧠 Tirzepatide doesn’t just reduce appetite—it rewires the brain.
- - -
A new Nature Medicine Phase 1 RCT (n=114) explored how tirzepatide changes eating behavior—and the brain’s response to food—in people with overweight or obesity.

📉 Key Findings at 3–6 Weeks
🔹-524 kcal/day